Acadian Asset Management
EPRX

Acadian Asset Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Acadian Asset Management’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$671K Sell
93,600
-62,166
-40% -$500K ﹤0.01% 1284
2025
Q4 		$1.17M Buy
155,766
+134,366
+628% +$828K ﹤0.01% 1077
2025
Q3 		$125K Buy
+21,400
New +$116K ﹤0.01% 1478

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Acadian Asset Management's EPRX Position: Q1 2026 in Review

Acadian Asset Management reduced its Eupraxia Pharmaceuticals (EPRX) stake by 40% in Q1 2026, selling an estimated $500K and leaving 93,600 shares worth $671K. The position accounts for ﹤0.01% of the portfolio, ranked #1284.

Acadian Asset Management first reported a position in EPRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.17M in Q4 2025. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Acadian Asset Management held 93,600 shares of Eupraxia Pharmaceuticals worth $671K as of Q1 2026.
  • Acadian Asset Management sold 62,166 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $500K.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1284 holding.
  • Acadian Asset Management first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Acadian Asset Management's Eupraxia Pharmaceuticals position peaked at $1.17M in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.